Epirus raises $36m for biosimilars, merges with Zalicus
This article was originally published in Scrip
Executive Summary
Biosimilar developer Epirus Biopharmaceuticals closed a $36m Series B venture financing round and gained access to the public fundraising market through a reverse merger with struggling pain drug developer Zalicus.